Related references
Note: Only part of the references are listed.Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer
Louise Carter et al.
NATURE MEDICINE (2017)
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
Jordi Bruix et al.
JOURNAL OF HEPATOLOGY (2017)
Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy
Glen J. Weiss et al.
CLINICAL CANCER RESEARCH (2017)
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma
J. H. Lee et al.
ANNALS OF ONCOLOGY (2017)
A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers
B. T. Li et al.
ANNALS OF ONCOLOGY (2016)
Changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response in metastatic cancers
Glen J. Weiss et al.
CANCER RESEARCH (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Genetic Landscape and Biomarkers of Hepatocellular Carcinoma
Jessica Zucman-Rossi et al.
GASTROENTEROLOGY (2015)
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial
Josep Tabernero et al.
LANCET ONCOLOGY (2015)
Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy
Atsushi Ono et al.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2015)
The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC
A. D. Nygaard et al.
BRITISH JOURNAL OF CANCER (2014)
Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab
Karina Dahl Steffensen et al.
EUROPEAN JOURNAL OF CANCER (2014)
Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma
Francois-Clement Bidard et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Human and Mouse VEGFA-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment
Elad Horwitz et al.
CANCER DISCOVERY (2014)
VEGFA Genomic Amplification Tailors Treatment of HCCs with Sorafenib
Xiaolin Luo et al.
CANCER DISCOVERY (2014)
DNA Ploidy is an Independent Predictor of Survival in Breast Invasive Ductal Carcinoma: A Long-term Multivariate Analysis of 393 Patients
Antonio E. Pinto et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Functional genomic analysis of chromosomal aberrations in a compendium of 8000 cancer genomes
Tae-Min Kim et al.
GENOME RESEARCH (2013)
Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma
Kai Wang et al.
HEPATOLOGY (2013)
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Muhammed Murtaza et al.
NATURE (2013)
Pan-cancer patterns of somatic copy number alteration
Travis I. Zack et al.
NATURE GENETICS (2013)
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah-Jane Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing
Ellen Heitzer et al.
GENOME MEDICINE (2013)
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
Josep M. Llovet et al.
CLINICAL CANCER RESEARCH (2012)
Summarizing and correcting the GC content bias in high-throughput sequencing
Yuval Benjamini et al.
NUCLEIC ACIDS RESEARCH (2012)
Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing
Rebecca J. Leary et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Overlapping High-Resolution Copy Number Alterations in Cancer Genomes Identified Putative Cancer Genes in Hepatocellular Carcinoma
Chian-Feng Chen et al.
HEPATOLOGY (2010)
The landscape of somatic copy-number alteration across human cancers
Rameen Beroukhim et al.
NATURE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma
Derek Y. Chiang et al.
CANCER RESEARCH (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma
Rameen Beroukhim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma
Y. Tokuhisa et al.
BRITISH JOURNAL OF CANCER (2007)
A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers
Scott L. Carter et al.
NATURE GENETICS (2006)
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling
JS Lee et al.
HEPATOLOGY (2004)
Share Paper
